(12) United States Patent (10) Patent No.: US 8,569,057 B2 Wehrman Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US008569057B2 (12) United States Patent (10) Patent No.: US 8,569,057 B2 Wehrman et al. (45) Date of Patent: Oct. 29, 2013 (54) MONITORING PROTEIN TRAFFICKING OTHER PUBLICATIONS USING BETA-GALACTOSIDASE REPORTER FRAGMENT COMPLEMENTATION Emr, et al., “Invertase beta-galactosidase hybrid proteins fail to be transported from the endoplasmic reticulum in Saccharomyces (75) Inventors: Thomas S. Wehrman, Mountain View, cerevisiae', Mol. Cell. Biol. 1984, 4(11):2347-2355. CA (US); Daniel Bassoni, Campbell, Drake, et al., “Trafficing of G protein-coupled receptors'. Circ. Research, Sep. 15, 2006, vol. 99, No. 6, pp. 570-582. CA (US); William Raab, San Francisco, International Search Report and Written Opinion, PCT/US 12/ CA (US) 043839, Sep. 7, 2012. Jin, et al. “Disease-associated mutations affect GPR56 protein traf (73) Assignee: DiscoveRx Corporation, Fremont, CA ficking and cell Surface expression'. Human Molecular Genetics, (US) 2007, vol. 16, No. 16, pp. 1972-1985. Mollinari, et al., “Role of EDEM in the release of misfolded (*) Notice: Subject to any disclaimer, the term of this glycoproteins from the calnexin cycle”. Science, vol. 299, Feb. 28. patent is extended or adjusted under 35 2003, pp. 1397-1400. U.S.C. 154(b) by 0 days. Conn, et al., “G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo”. Pharmacological Reviews, vol. 59, No. 3, 2007, pp. 225-250. (21) Appl. No.: 13/531,230 Stephenson, "Structure and trafficking of NMDA and GABA-a receptors'. Biochemical Society Transactions (2006) vol. 34, part 5, (22) Filed: Jun. 22, 2012 pp. 877-881. Petaja-Repo, et al., “Ligands act as pharmacological chaperones and (65) Prior Publication Data increase the efficiency of delta opioid receptor maturation'. The EMBO Journal, vol. 21, No. 7, 2002, pp. 1628-1637. US 2012/0329075A1 Dec. 27, 2012 Lilley, et al. A membrane protein required for dislocation of misfolded proteins from the ER', Nature, vol. 429, Jun. 24, 2004, pp. 834-840. Related U.S. Application Data Li, et al., “Bone morphogenetic protein type II receptor mutations causing protein misfolding inheritable pulmonary arterial hyperten (60) Provisional application No. 61/571,315, filed on Jun. sion”. Proceedings of the American Thoracic Society, vol. 7, 2010, 23, 2011. pp. 395-398. Zeng, et al., “Conserved extracellular cysteine pair in the M3 (51) Int. Cl. muscarinic acetylcholine receptor is essential for proper receptor cell CI2N 5/02 Surface localization but not for G protein coupling'. Journal of (2006.01) Neurochemistry, 72, 1999, pp. 2404-2414. (52) U.S. Cl. Hammer, et al., “A novel enzyme complementation-based assay for USPC .......................................................... 435/375 monitoring G-protein-coupled receptor internalization'. The FASEB (58) Field of Classification Search Journal, vol. 21, Dec. 2007, pp. 3827-3834. None Dong, et al., “Regulation of G protein-coupled receptor export traf See application file for complete search history. ficking, Biochim Biophys Acta., Apr. 2007: 1768(4): 853-870. Primary Examiner — Michael Pak (56) References Cited (74) Attorney, Agent, or Firm — David J. Aston; Peters U.S. PATENT DOCUMENTS Verny, LLP 4,378.428 A 3, 1983 Farina et al. (57) ABSTRACT 4,708,929 A 11, 1987 Henderson 5,037,735 A 8, 1991 Khanna et al. Methods and materials are disclosed for use in an enzyme 5,106,950 A 4, 1992 Farina et al. fragment complementation assay using complementary frag 5,362.625 A 11/1994 Krevolin et al. 5,464,747 A 11/1995 Eisenbeis et al. ments off-galactosidase to study the trafficking of proteins in 5,604,091 A 2f1997 Henderson a cell. Compounds that bind to a target peptide have been 5,643,734 A 7, 1997 Henderson found to affect protein folding and therefore trafficking. 2003/0219848 A1 1 1/2003 Naqvi et al. B-Galactosidase fragments, an enzyme donor (ED) and an 2007/0275397 A1 11/2007 Wehrman et al. 2009/0098588 A1 4/2009 Wehrman et al. enzyme acceptor (EA), are fused to a target peptide and to an 2010.004 1052 A1 2/2010 Feng et al. intracellular compartment protein, wherein the compartment 2010, 0120063 A1 5/2010 Bassoni et al. is involved in intracellular trafficking. Contacting the cell 2010/02O3555 A1 8, 2010 Wehrman et al. 2010/0285451 A1 11/2010 Blau et al. with a compound that binds to the target peptide results in 2011/O130543 A1 6, 2011 Stevens et al. enhanced movement of the protein through the cellular traf ficking pathway comprised of the endoplasmic reticulum, FOREIGN PATENT DOCUMENTS Golgi apparatus, the plasma membrane, endosomes, etc. Using this approach, compounds that bind to a target peptide WO 92.03559 A2 3, 1992 WO 96, 19732 A1 6, 1996 and alter its ability to traffic through the normal cellular WO OO,39348 A1 T 2000 pathway can be readily detected. WO 01 00214 A1 1, 2001 WO 01.60840 A2 8, 2001 8 Claims, 6 Drawing Sheets U.S. Patent Oct. 29, 2013 Sheet 1 of 6 US 8,569,057 B2 PM 4 ProLinkTM / Figure 1 U.S. Patent Oct. 29, 2013 Sheet 2 of 6 US 8,569,057 B2 O. +test compoundA . 202 . i. th a Figure 2 U.S. Patent Oct. 29, 2013 Sheet 3 of 6 US 8,569,057 B2 Ion Channel Trafficking Generating Figure 3 U.S. Patent Oct. 29, 2013 Sheet 4 of 6 US 8,569,057 B2 U2OS Endo-EA ADRB2(W158A)-PK Clone 175OO 15OOO 125OO 1 OOOO 75OO 5OOO 25OO O 10-11 10-10 10-9 10-8 10-7 10-6 10-5 Propanolol (M) Figure 4 U.S. Patent Oct. 29, 2013 Sheet 5 of 6 US 8,569,057 B2 U2OS 5-EAPLC(PH)-Ea KCNH2-PK (mut) 35000 E. Clofilium A Haloperidol V Astemizole 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4 Compound (M) Figure 5 U.S. Patent Oct. 29, 2013 Sheet 6 of 6 US 8,569,057 B2 U20S5-EAPLC(PH)-EACHRM4(DC)-PK 60000 LY2033298 50000 A WUO239429 40000 v VU10010 O 4 OXOM 30000 O XanOmeline Oxalate 20000 4-DAMP 10000 109 108 O-7 06 0-5 10-4 103 10-2 Compound (M) Figure 6 US 8,569,057 B2 1. 2 MONITORNG PROTEIN TRAFFICKING LF Jr., 1994 GCRDb: a G-protein-coupled receptor database, USING BETA-GALACTOSIDASE REPORTER Receptors Channels 2 (1): 1-7: Foord S. M. Bonner T I, FRAGMENT COMPLEMENTATION Neubig RR, Rosser EM, Pin JP, Davenport AP Spedding M, Harmar A. J. 2005, International Union of Pharmacology. CROSS-REFERENCE TO RELATED XLVI.G protein-coupled receptor list, Pharmacol Rev 57(2): APPLICATIONS 279-88, InterPro). GPCR's broadly can be grouped into six classes based on sequence homology and functional similar This application claims priority from U.S. Provisional ity, as follows. Patent Application No. 61/571,315 filed on Jun. 23, 2011, which is hereby incorporated by reference. 10 STATEMENT OF GOVERNMENTAL SUPPORT Class A (Rhodopsin-like) Class B (Secretin receptor family) Class C (Metabotropic glutamate?pheromone) None. Class D (Fungal mating pheromone receptors) 15 Class E (Cyclic AMP receptors) REFERENCE TO SEQUENCE LISTING, Class F (Frizzled Smoothened) COMPUTER PROGRAM, OR COMPACT DISK A GPCR adopts a tertiary structure with the seven trans The instant application contains a Sequence Listing which membrane helices which forms a cavity within the plasma has been submitted as an ASCII text file and is hereby incor membrane and the cavity serves as a ligand-binding domain. porated by reference in its entirety. This text file was created Another common structural feature amongst GPCRs is on Jun. 21, 2012, is named “3817 36 1 Seq List.txt and palmitoylation of one or more sites of the C-terminal tail or is 12.412 bytes in size. the intracellular loops which has the effect of targeting the BACKGROUND OF THE INVENTION 25 receptor to cholesterol and sphingolipid-rich microdomains of the plasma membrane called lipid rafts and have a role to 1. Field of the Invention participate in rapid receptor signaling. The present invention relates to the field of assays for Ion channels represent another class of membrane protein measuring the intracellular movement (“trafficking) of pro complexes that play an important function of facilitating the teins containing at least one transmembrane domain, such as 30 diffusion of ions across the biological membranes. They act a cell Surface receptor. as electrical insulators and provide a high conducting, hydro 2. Related Art philic pathway across the hydrophobic interior of the mem Presented below is background information on certain brane. Their mode of action is highly gated and they switch aspects of the present invention as they may relate to technical their confirmations between closed and open States. Depend features referred to in the detailed description, but not neces 35 ing on the chemical and physical modulators that control the sarily described in detail. That is, individual parts or methods gating activity-ion channels can be classified into the follow used in the present invention may be described in greater ing groups: detail in the materials discussed below, which materials may 1. Ligand-gated channels provide further guidance to those skilled in the art for making 2. Voltage-gated channels or using certain aspects of the present invention as claimed. 40 The discussion below should not be construed as an admis 3. Second-messenger gated channels sion as to the relevance of the information to any claims 4. Mechanosensitive channels herein or the prior art effect of the material described. 5. Gap junctions Protein synthesis and its processing are highly regulated There area number of human disorders that can result from events done in a tightly scrutinized and controlled manner at 45 the transcriptional, translational and post-translational levels misfolded/mutated protein ion channels.